Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy - ScienceDirect

Toxicity and management in CAR T-cell therapy: Molecular Therapy - Oncolytics

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target, Experimental Hematology & Oncology

Frontiers Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B- cell lymphomas

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies - Kampouri - 2023 - Transplant Infectious Disease - Wiley Online Library

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy: Molecular Therapy

Frontiers Broadening the horizon: potential applications of CAR-T cells beyond current indications

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. - Abstract - Europe PMC

CAR T-Cell Therapy

Pharmacomicrobiomics: The universe of microbiome-drug interactions - Microbiome Times Magazine

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

IJMS, Free Full-Text